2009 January
Comparative Analysis of MesenchymalStem Cells from Bone Marrow,Umbilical Cord Blood, orAdipose Tissue.
Mesenchymal stem cells (MSCs) represent a promising tool for new clinical concepts in supporting cellular therapy.
2014 January
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for theTreatment of Chronic DiscogenicLow Back Pain.
Human umbilical cord tissue-derived mesenchymal stem cells (HUC-MSCs) contain stem cells and possess the ability to regenerate degenerative discs.
2014 May
Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia inpatients with type 2 diabetes mellitus.
Type 2 diabetes mellitus (T2DM) is a serious threat to human health and remains incurable.
2015 May
Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells inpatients with type 2 diabetes.
Type 2 diabetes (T2D) is characterized by progressive and inexorable β-cell dysfunction, leading to insulin deficiency.
2015 June
Umbilical cord blood donation: public or private?
Umbilical cord blood (UCB) is a graft source for patients with malignant or genetic diseases who can be cured by allogeneic hematopoietic cell transplantation (HCT), but who do not have an appropriately HLA-matched family or volunteer unrelated adult donor.
2015 July
Transplantation of umbilical cord blood mononuclear cells increases levels ofnerve growth factor in the cerebrospinalfluid of patients with autism.
We aimed to evaluate the levels of growth factors in the cerebrospinal fluid (CSF) of patients with autism after transplantation of umbilical cord blood mononuclear cells (CBMNCs).
2016 February
Time related variations in stem cell harvesting of umbilical cord blood.
Umbilical cord blood (UCB) contains hematopoietic stem cells and multipotent mesenchymal cells useful for treatment in malignant/nonmalignant hematologic-immunologic diseases and regenerative medicine.
2016 February
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey.
2017 February
Genetically re-engineered K562 cells significantly expand and functionallyactivate cord blood natural killer cells: Potential for adoptive cellularimmunotherapy
Cord blood (CB) mononuclear cells were expanded with artificial antigen-presenting cells.
2017 April
Umbilical Cord Blood Transplantation: Challengesand Future Directions.
An exciting new development is the use of either autologous or unrelated UCBT for nontraditional applications (outside of oncology) in neurology, endocrinology, and cardiology, for diseases that have significant worldwide impact.
2017 April
Autologous Cord Blood Infusions Are Safe andFeasible in Young Children with AutismSpectrum Disorder: Results of a Single‐CenterPhase I Open‐Label Trial.
Despite advances in early diagnosis and behavioral therapies, more effective treatments for children with autism spectrum disorder (ASD) are needed.
2017 April
A History of Cord Blood Banking andTransplantation.
Cord blood is not just a “bag of blood stem cells,” and newer therapies are leveraging the activities of monocytes and other cells in the mix.
2017 June
Anticancer cellular immunotherapies taken from umbilical cord blood.
The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies.
2017 August
Update on umbilical cord blood transplantation.
Allogeneic hematopoietic cell transplant is a curative procedure for many patients with leukemia, lymphoma, myelodysplasia, myeloproliferative neoplasms, and genetic disorders.
2017 October
Effect of Autologous Cord Blood Infusionon Motor Function and Brain Connectivity in Young Children with Cerebral Palsy:A Randomized, Placebo‐Controlled Trial.
Cerebral palsy (CP) is a condition affecting young children that causes lifelong disabilities. Umbilical cord blood cells improve motor function in experimental systems via paracrine signaling.
2017 November
The first decade of advanced cell therapy clinicaltrials using perinatal cells.
Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase.
2017 November
The first decade of advanced cell therapy clinicaltrials using perinatal cells.
Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase.
2017 November
Cord Blood Banking for Potential Future Transplantation.
This policy statement is intended to provide information to guide pediatricians, obstetricians, and other medical specialists and health care providers in responding to parents’ questions about cord blood donation and banking as well as the types (public versus private) and quality of cord blood banks.
2018 April
Safety and Observations from a Placebo‐Controlled, Crossover Study to Assess Use of AutologousUmbilical Cord Blood Stem Cells to ImproveSymptoms in Children with Autism.
The aim of this exploratory study was to assess the safety and clinical effects of autologous umbilical cord blood (AUCB) infusion in children with idiopathic autism spectrum disorder (ASD).
2018 May
Allogeneic Umbilical Cord Blood Infusion for Adultswith Ischemic Stroke: Clinical Outcomes froma Phase I Safety Study.
Stroke is a major cause of death and long‐term disability, affecting one in six people worldwide.
2018 July
Cord Blood Infusion for Children With AutismSpectrum Disorder (Duke ACT).
This is a single site, prospective, randomized, double-blind study of a single intravenous autologous or allogeneic, unrelated cord blood (CB) infusion in children ages 2-7 years with Autism Spectrum Disorder (ASD).
2018 July
Repurposing the Cord Blood Bank for Haplobankingof HLA‐Homozygous iPSCs and TheirUsefulness to Multiple Populations.
Although autologous induced pluripotent stem cells (iPSCs) can potentially be useful for treating patients without immune rejection, in reality it will be extremely expensive and labor‐intensive to make iPSCs to realize personalized medicine.
2018 August
Safety of Autologous Umbilical Cord Blood Therapyfor Acquired Sensorineural Hearing Loss inChildren.
Sensorineural hearing loss (SNHL) in children is associated with neurocognitive morbidity. The cause of SNHL is a loss of hair cells in the organ of Corti.
2018 August
Advances in perinatal stem cells research: Aprecious cell source for clinical applications.
Perinatal tissues possess numerous types of stem (stromal) cells, which are considered effective candidates for cell therapy.
2018 September
Factors Influencing the rise ofUmbilical Blood Cell's Stem Cell Industry.
The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies.
2018 September
Indications for Utilization of Stored Umbilical Cord Blood.
Since the first umbilical cord blood transplantation in 1988 for Fanconi’s anemia (1), umbilical cord blood has become a safe and dependable alternative donor graft source for use in allogeneic hematopoietic cell transplantation.
2018 September
Factors Influencing the Umbilical Cord Blood StemCell Industry: An Evolving Treatment Landscape.
Hematopoietic stem cell transplantation (HSCT) is common practice today for life threatening malignant and non‐malignant diseases of the blood and immune systems.
2018 November
Current and future status of stem cell expansion.
Decreased number of stem cells contained in a cord blood unit and early differentiation of stem cells once expanded have been two overarching challenges faced by the field.
2018 December
Umbilical Cord‐Derived Mesenchymal Stromal Cells (MSCs) forKnee Osteoarthritis.
The lack of highly effective drugs in many malignancies has prompted scientific interest in the development of alternative treatment strategies.
